Registration

SOR/2015-192 July 16, 2015

CONTROLLED DRUGS AND SUBSTANCES ACT

Order Amending Schedule II to the Controlled Drugs and Substances Act (Synthetic Cannabinoids)

P.C. 2015-1082 July 16, 2015

His Excellency the Governor General in Council, on the recommendation of the Minister of Health, pursuant to section 60 of the Controlled Drugs and Substances Act , deeming that it is necessary in the public interest, makes the annexed Order Amending Schedule II to the Controlled Drugs and Substances Act (Synthetic Cannabinoids).

ORDER AMENDING SCHEDULE II TO THE CONTROLLED DRUGS AND SUBSTANCES ACT (SYNTHETIC CANNABINOIDS)

AMENDMENTS

1. (1) The portion of item 1 of Schedule II to the Controlled Drugs and Substances Act before subitem (1) is replaced by the following:

1. Cannabis, its preparations and derivatives, including

(2) Subitems 1(5), (6) and (7.1) of Schedule II to the Act are repealed.

2. Schedule II to the Act is amended by adding the following after item 1:

2. Synthetic cannabinoid receptor type 1 agonists, their salts, derivatives, isomers, and salts of derivatives and isomers — with the exception of ((3S)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl)-1-naphthalenyl-methanone (WIN 55,212-3) and its salts — including those that fall within the following core chemical structure classes:

(1) Any substance that has a 2-(cyclohexyl)phenol structure with substitution at the 1-position of the benzene ring by a hydroxy, ether or ester group and further substituted at the 5-position of the benzene ring, whether or not further substituted on the benzene ring to any extent, and substituted at the 3’-position of the cyclohexyl ring by an alkyl, carbonyl, hydroxyl, ether or ester, and whether or not further substituted on the cyclohexyl ring to any extent, including

(i) Nabilone ((±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one)

(ii) Parahexyl (3-hexyl-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-1-ol)

(iii) 3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol (DMHP)

(iv) 5-(1,1-dimethylheptyl)-2-(5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)phenol (CP 55,940)

(v) 5-(1,1-dimethylheptyl)-2-(3-hydroxycyclohexyl)phenol (CP 47,497)

(2) Any substance that has a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent and whether or not substituted on the naphthyl ring to any extent, including

(i) 1-pentyl-3-(1-naphthoyl)indole (JWH-018)

(ii) 1-butyl-3-(1-naphthoyl)indole (JWH-073)

(iii) 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)

(iv) 1-hexyl-3-(1-naphthoyl)indole (JWH-019)

(v) 1-(4-pentenyl)-3-(1-naphthoyl)indole (JWH-022)

(vi) 1-butyl-3-(4-methoxy-1-naphthoyl)indole (JWH-080)

(vii) 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081)

(viii) 1-(2-morpholin-4-ylethyl)-3-(1naphthoyl)indole (JWH-200)

(ix) 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210)

(x) 1-pentyl-3-(2-methoxy-1-naphthoyl)indole (JWH-267)

(xi) 1-[(N-methylpiperidin-2-yl)methyl]-3(1-naphthoyl)indole (AM-1220)

(xii) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201)

(xiii) 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole (MAM-2201)

(xiv) 1-(5-fluoropentyl)-3-(4-ethyl-1-naphthoyl)indole (EAM-2201)

(xv) ((3R)-2,3-dihydro-5-methyl-3(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl)-1-naphthalenyl-methanone (WIN 55,212-2)

(3) Any substance that has a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted on the pyrrole ring to any extent and whether or not substituted on the naphthyl ring to any extent, including

(i) 1-pentyl-5-(2-fluorophenyl)-3-(1-naphthoyl)pyrrole (JWH-307)

(4) Any substance that has a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent and whether or not substituted on the phenyl ring to any extent, including

(i) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)

(ii) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251)

(iii) 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH-302)

(5) Any substance that has a 3-benzoylindole structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent and whether or not substituted on the phenyl ring to any extent, including

(i) 1-(1-methylpiperidin-2-ylmethyl)-3-(2-iodobenzoyl)indole (AM-2233)

(6) Any substance that has a 3-methanone(cyclopropyl)indole structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent and whether or not substituted on the cyclopropyl ring to any extent, including

(i) (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone (UR-144)

(ii) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone (5F-UR-144)

(iii) (1-(2-(4-morpholinyl)ethyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone (A-796,260)

(7) Any substance that has a quinolin-8-yl 1H-indole-3-carboxylate structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent and whether or not substituted on the quinolin-8-yl ring to any extent, including

(i) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22)

(ii) 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid (5F-PB-22)

(8) Any substance that has a 3-carboxamideindazole structure with substitution at the nitrogen atom of the indazole ring, whether or not further substituted on the indazole ring to any extent and whether or not substituted at the carboxamide group to any extent, including

(i) N-(adamantan-1-yl)-1-pentyl-1H-indazole-3-carboxamide (AKB48)

(ii) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-AKB48)

(iii) N-(1-(aminocarbonyl)-2-methylpropyl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA)

(iv) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA)

(9) Any substance that has a 3-carboxamideindole structure with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent and whether or not substituted at the carboxamide group to any extent, including

(i) N-(adamantan-1-yl)-1-fluoropentylindole-3-carboxamide (STS-135)

(ii) N-(adamantan-1-yl)-1-pentylindole-3-carboxamide (APICA)

COMING INTO FORCE

3. This Order comes into force on the day on which it is registered.

N.B. The Regulatory Impact Analysis Statement for this Order appears following SOR/2015-191, Regulations Amending the Narcotic Control Regulations (Synthetic Cannabinoids).